Compare XPOF & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | CGEN |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 191.1M |
| IPO Year | 2021 | 2001 |
| Metric | XPOF | CGEN |
|---|---|---|
| Price | $3.73 | $2.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $8.13 | $5.00 |
| AVG Volume (30 Days) | ★ 638.3K | 184.2K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.63 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.57 | $1.38 |
| 52 Week High | $9.25 | $3.24 |
| Indicator | XPOF | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 32.43 | 41.25 |
| Support Level | N/A | $2.34 |
| Resistance Level | $6.15 | $2.54 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 14.08 | 14.06 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.